AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11149995 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine premedication
Number of subjects: 47
Study 11149995 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 47
Study 9562219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilatator
Number of subjects: 10
Study 7829945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone tablets (1 mg/kg body wt/day up to 70 mg) for six successive days, then gradually reduced over the next four days
Number of subjects: 160
Study 7829945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 160
Study 3341273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (90 mg/m2 given over 2 days, once a month for 5 months)
Number of subjects: 119
Study 3341273 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 119
Study 1299795 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 48
Study 1299795 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 48
Study 1299795 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine or breakfast)
Number of subjects: 48
Study 330893 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 30
Study 330893 — intervention group
Group type: COMPARATOR
Intervention: Inert aerosol placebo
Number of subjects: 30
Study 330893 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol after placebo
Number of subjects: 30
Study 30334166 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical surgical trainer
Number of subjects: 18
Study 30334166 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual trainer
Number of subjects: 18
Study 30334166 — intervention group
Group type: COMPARATOR
Intervention: Untrained subjects
Number of subjects: 18
Study 28134056 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led caregiver delivered rehabilitation program after stroke
Number of subjects: 0
Study 28134056 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26012577 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 150
Study 26012577 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 150
Study 25675798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal ectopic pregnancy (EP) group
Number of subjects: 157
Study 25675798 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy intrauterine gestations)
Number of subjects: 157
Study 22479375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material (photo-novel) tailored to increase knowledge about SPC screening
Number of subjects: 326
Study 22479375 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 326
Study 22479375 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 326
Study 19104452 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein S-100B assessment
Number of subjects: 97
Study 19104452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase (LDH) assessment
Number of subjects: 97
Study 19104452 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100B assessment
Number of subjects: 97
Study 17542353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecital 40 mg
Number of subjects: 24
Study 17542353 — intervention group
Group type: COMPARATOR
Intervention: Cipramil 40 mg
Number of subjects: 24
Study 15601422 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 66
Study 15601422 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib
Number of subjects: 66
Study 15601422 — intervention group
Group type: COMPARATOR
Intervention: cisapride (positive control)
Number of subjects: 66
Study 15601422 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 11384657 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch
Number of subjects: 16
Study 11384657 — intervention group
Group type: COMPARATOR
Intervention: human albumin
Number of subjects: 16
Study 9709042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (4 mg)
Number of subjects: 144
Study 9709042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 144
Study 9709042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 11271219 — intervention group
Group type: COMPARATOR
Intervention: OKT3 (n=15)
Number of subjects: 38
Study 11271219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulins (ALG) (n=23)
Number of subjects: 38
Study 11271219 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 38
Study 11271219 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 38
Study 2597714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-change group
Number of subjects: 30
Study 2597714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte-change group
Number of subjects: 30
Study 5800368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose infusion
Number of subjects: 19
Study 31894615 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with ID
Number of subjects: 81510
Study 31894615 — intervention group
Group type: COMPARATOR
Intervention: Youth without ID
Number of subjects: 81510
Study 31424712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2058
Study 31424712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2058
Study 28282703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 80
Study 28282703 — intervention group
Group type: COMPARATOR
Intervention: Water spray (placebo)
Number of subjects: 80
Study 25923479 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (4 x 10 gram aliquots) during unilateral resistance training
Number of subjects: 12
Study 25923479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) during unilateral resistance training
Number of subjects: 12
Study 23833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.454% w/w stannous fluoride
Number of subjects: 137
Study 23833917 — intervention group
Group type: COMPARATOR
Intervention: Marketed control dentifrice containing 0.76% w/w sodium monofluorophosphate (Colgate Cavity Protection)
Number of subjects: 137
Study 23833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed comparator dentifrice containing 0.454% w/w stannous fluoride (Crest Pro‐Health ‐ Clean Mint)
Number of subjects: 137
Study 21618201 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg SC on days 1 and 8, then weekly; plus IV loading dose ∼10 mg/kg on day 1)
Number of subjects: 1457
Study 21618201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abatacept (∼10 mg/kg on days 1, 15, and 29, then every 4 weeks)
Number of subjects: 1457
Study 21618201 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 1457
Study 21618201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abatacept
Number of subjects: 1457
Study 19813273 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PSA-screening every second year (attendees)
Number of subjects: 10000
Study 19813273 — intervention group
Group type: COMPARATOR
Intervention: Nonattendees (not participating in screening)
Number of subjects: 10000
Study 16961169 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin preparation 1 (400 mg)
Number of subjects: 26
Study 16961169 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin preparation 2 (400 mg)
Number of subjects: 26
Study 15569517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dipterex poisoning (ADPP)
Number of subjects: 82
Study 10876451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine‐‐2.5% prilocaine cream (LPC)
Number of subjects: 280
Study 10876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorotetrafluoroethane spray (DCTF)
Number of subjects: 280
Study 10876451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 280
Study 10876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with 0.9% benzyl alcohol (BA)
Number of subjects: 280
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposals for harmonizing assessment of outcomes and predictors in rehabilitation studies.
Number of subjects: 0
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept for pre-post and follow-up measurement in rehabilitation studies.
Number of subjects: 0
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptions of self-assessment instruments for cross-study comparisons.
Number of subjects: 0
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure to assess direct and indirect costs of rehabilitation.
Number of subjects: 0
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisions for ensuring representativeness of women in intervention studies.
Number of subjects: 0
Study 9490458 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a coordination committee for harmonization.
Number of subjects: 0
Study 1396258 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy with oxytocin
Number of subjects: 0
Study 1396258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous professional support during labour
Number of subjects: 0
Study 1396258 — intervention group
Group type: COMPARATOR
Intervention: Intermittent presence of a member of staff
Number of subjects: 0
Study 3926510 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (300 mmol)
Number of subjects: 25
Study 3926510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (50-100 mmol)
Number of subjects: 25
Study 3926510 — intervention group
Group type: COMPARATOR
Intervention: Control period (normal sodium intake)
Number of subjects: 25
Study 3926510 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg per kg body weight) administered intravenously
Number of subjects: 25
Study 30877090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 2155
Study 30877090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study 30035581 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 180
Study 30035581 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only treatment as usual (TAU)
Number of subjects: 180
Study 28376282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 110
Study 28376282 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 110
Study 28376282 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy (RT)
Number of subjects: 110
Study 25750322 — intervention group
Group type: EXPERIMENTAL
Intervention: P53-positive tumors (nuclear expression in >10% of cells or absent pattern)
Number of subjects: 884
Study 25750322 — intervention group
Group type: COMPARATOR
Intervention: P53-negative tumors (nuclear expression in <10% of cells)
Number of subjects: 884
Study 23855131 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sodium restricted diet with diuretics (sodium chloride 6500-8000 mg daily)
Number of subjects: 80
Study 23855131 — intervention group
Group type: COMPARATOR
Intervention: Sodium restricted diet with diuretics (sodium chloride 5000 mg daily)
Number of subjects: 80
Study 20525111 — intervention group
Group type: EXPERIMENTAL
Intervention: HeRO Vascular Access Device
Number of subjects: 1
Study 18563956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 5 mg
Number of subjects: 50
Study 18563956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 5 mg
Number of subjects: 50
Study 18563956 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aripiprazole 2 mg
Number of subjects: 50
Study 18563956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole (doses from 1 mg to 45 mg)
Number of subjects: 50
Study 16369989 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered at 20 mg/m2/day for 5 days a week for 2 consecutive weeks, repeated every 4 weeks for at least 2 courses.
Number of subjects: 32
Study 14717271 — intervention group
Group type: EXPERIMENTAL
Intervention: FluMist (intranasal flu vaccine)
Number of subjects: 0
Study 11326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg orally for 2 days (total 150 mg) + misoprostol 0.6 mg orally every 3-4 hours for 3 times
Number of subjects: 2007
Study 11326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg orally for 2 days (total 200 mg) + misoprostol 0.6 mg orally every 3-4 hours for 3 times
Number of subjects: 2007
Study 11326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg orally for 2 days (total 150 mg) + misoprostol vaginally every 12 hours for 3 times
Number of subjects: 2007
Study 11326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg orally for 2 days (total 200 mg) + misoprostol vaginally every 12 hours for 3 times
Number of subjects: 2007
Study 11326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal route
Number of subjects: 2007
Study 8735776 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron solution with ascorbic acid added to domestic drinking water for 4 months
Number of subjects: 88
Study 8735776 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 88
Study 1750592 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg night sedation
Number of subjects: 6
Study 1750592 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg night sedation
Number of subjects: 6
Study 1750592 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo night sedation
Number of subjects: 6
Study 1750592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 5 mg
Number of subjects: 6
Study 6117662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bethanechol chloride
Number of subjects: 0
Study 6117662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31135731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (glucose measurements hourly and treatment for maternal glucose levels lower than 60 mg/dL or greater than 100 mg/dL)
Number of subjects: 76
Study 31135731 — intervention group
Group type: COMPARATOR
Intervention: Liberalized control (glucose measurements every 4 hours and treatment for maternal glucose levels lower than 60 mg/dL or greater than 120 mg/dL)
Number of subjects: 76
Study 31135731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 76
Study 31135731 — intervention group
Group type: COMPARATOR
Intervention: Liberalized control
Number of subjects: 76
Study 28543940 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg monthly)
Number of subjects: 128
Study 28543940 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide (20 μg daily)
Number of subjects: 128
Study 28543940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 25452626 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-only CR
Number of subjects: 169
Study 25452626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex CR
Number of subjects: 169
Study 25452626 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based CR
Number of subjects: 169
Study 25452626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction across all models
Number of subjects: 169
Study 22841526 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL/kg of 7.2% NaCl/hydroxyethyl starch (HSH group)
Number of subjects: 26
Study 22841526 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 26
Study 21719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care for children with leukaemia who survived SAEV
Number of subjects: 88
Study 21719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Children requiring haemodialysis
Number of subjects: 88
Study 21719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Children requiring cardiac resuscitation
Number of subjects: 88
Study 21719441 — intervention group
Group type: COMPARATOR
Intervention: Patients with more than three identified risk factors
Number of subjects: 88
Study 21719441 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL and AML patients with SAEV
Number of subjects: 88
Study 19219022 — intervention group
Group type: EXPERIMENTAL
Intervention: tat‐vpr‐specific anti‐HIV ribozyme (OZ1)
Number of subjects: 74
Study 19219022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 16421186 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 60
Study 16421186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12709693 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious analgesia/sedation with remifentanil (0.20 to 0.25 microg/kg/min) and propofol
Number of subjects: 100
Study 12709693 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) with fentanyl (2 microg/kg), midazolam (0.05 mg/kg), and propofol
Number of subjects: 100
Study 12709693 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious analgesia/sedation with remifentanil and propofol
Number of subjects: 100
Study 12709693 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 100
Study 10862445 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (2 g daily)
Number of subjects: 53
Study 10862445 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (2 g daily)
Number of subjects: 53
Study 10862445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study 1486118 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 reinjection at rest after conventional stress-redistribution imaging (88 patients)
Number of subjects: 143
Study 1486118 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 reinjection at rest on a separate day (55 patients)
Number of subjects: 143
Study 1486118 — intervention group
Group type: COMPARATOR
Intervention: Conventional stress-redistribution imaging
Number of subjects: 143
Study 3030864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination measles, mumps, rubella, varicella vaccine (MMRV)
Number of subjects: 20
Study 3030864 — intervention group
Group type: COMPARATOR
Intervention: Standard measles, mumps, rubella vaccine and subsequent varicella vaccine (MMR + V)
Number of subjects: 20
Study 3030864 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 20
Study 3030864 — intervention group
Group type: COMPARATOR
Intervention: MMR + V
Number of subjects: 20
Study 31446581 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.6-μm infrared laser moxibustion
Number of subjects: 143
Study 31446581 — intervention group
Group type: COMPARATOR
Intervention: Traditional moxibustion
Number of subjects: 143
Study 30541224 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour training program with the theme of expressing empathy to patients using a role-playing technique
Number of subjects: 77
Study 30541224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 27705267 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab + Lenalidomide + Dexamethasone
Number of subjects: 569
Study 27705267 — intervention group
Group type: COMPARATOR
Intervention: Control (Lenalidomide + Dexamethasone)
Number of subjects: 569
Study 24434732 — intervention group
Group type: EXPERIMENTAL
Intervention: SCION-PAIN program (multimodular structured intervention)
Number of subjects: 263
Study 24434732 — intervention group
Group type: EXPERIMENTAL
Intervention: SCION-PAIN program
Number of subjects: 263
Study 24434732 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 263
Study 22580235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNAse 2.5 mg
Number of subjects: 50
Study 22580235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNAse 5.0 mg
Number of subjects: 50
Study 22580235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNAse 7.5 mg
Number of subjects: 50
Study 22580235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22580235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNAse (all doses)
Number of subjects: 50
Study 20074264 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy
Number of subjects: 200
Study 20074264 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 200
Study 20074264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 17462643 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU hCG every other day for 3 weeks
Number of subjects: 29
Study 17462643 — intervention group
Group type: COMPARATOR
Intervention: T administration alone
Number of subjects: 29
Study 17462643 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (0, 125 IU, 250 IU, or 500 IU every other day) for 3 weeks
Number of subjects: 29
Study 16179085 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-MB (25 mg/kg CQ and 12 mg/kg MB over three days)
Number of subjects: 226
Study 16179085 — intervention group
Group type: COMPARATOR
Intervention: CQ (25 mg/kg over three days)
Number of subjects: 226
Study 16179085 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-MB and CQ
Number of subjects: 226
Study 12427142 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (administered at a reduced dose frequency)
Number of subjects: 522
Study 12427142 — intervention group
Group type: COMPARATOR
Intervention: rHuEPO (administered at standard frequency)
Number of subjects: 522
Study 12427142 — intervention group
Group type: COMPARATOR
Intervention: Comparison of darbepoetin alfa and rHuEPO
Number of subjects: 522
Study 12427142 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa and rHuEPO
Number of subjects: 522
Study 10520780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography (LLEE)
Number of subjects: 52